NO20040479L - Solvater av lerkanidipinhydroklorid og nye krystallinske former av lerkanidipinhydroklorid. - Google Patents

Solvater av lerkanidipinhydroklorid og nye krystallinske former av lerkanidipinhydroklorid.

Info

Publication number
NO20040479L
NO20040479L NO20040479A NO20040479A NO20040479L NO 20040479 L NO20040479 L NO 20040479L NO 20040479 A NO20040479 A NO 20040479A NO 20040479 A NO20040479 A NO 20040479A NO 20040479 L NO20040479 L NO 20040479L
Authority
NO
Norway
Prior art keywords
lercanidipine hydrochloride
solvates
crystalline forms
new crystalline
lercanidipine
Prior art date
Application number
NO20040479A
Other languages
English (en)
Norwegian (no)
Inventor
Amedo Leonardi
Fausto Bonifacio
Gianluca De Lasi
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of NO20040479L publication Critical patent/NO20040479L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20040479A 2001-08-06 2004-02-03 Solvater av lerkanidipinhydroklorid og nye krystallinske former av lerkanidipinhydroklorid. NO20040479L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI001727A ITMI20011727A1 (it) 2001-08-06 2001-08-06 Solvati della lercanidipina cloridrato e nuove forme cristalline della lercanidipina cloridrato ottenute da essi
PCT/EP2002/008700 WO2003014085A1 (en) 2001-08-06 2002-08-05 Solvates of lercanidipine hydrochloride and new crystalline forms of lercanidipine hydrochloride

Publications (1)

Publication Number Publication Date
NO20040479L true NO20040479L (no) 2004-02-03

Family

ID=11448246

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040479A NO20040479L (no) 2001-08-06 2004-02-03 Solvater av lerkanidipinhydroklorid og nye krystallinske former av lerkanidipinhydroklorid.

Country Status (21)

Country Link
EP (1) EP1423367B1 (de)
JP (1) JP2005502648A (de)
KR (1) KR100912664B1 (de)
CN (1) CN100494175C (de)
AR (1) AR037230A1 (de)
AT (1) ATE294162T1 (de)
AU (1) AU2002331390B2 (de)
BR (1) BR0211738A (de)
DE (1) DE60203919D1 (de)
EA (1) EA200400279A1 (de)
ES (1) ES2209684T1 (de)
HR (1) HRP20040157A2 (de)
HU (1) HUP0401161A3 (de)
IL (2) IL153916A0 (de)
IT (1) ITMI20011727A1 (de)
MX (1) MXPA04001073A (de)
NO (1) NO20040479L (de)
PE (1) PE20030350A1 (de)
PL (1) PL369449A1 (de)
UY (1) UY27409A1 (de)
WO (1) WO2003014085A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100651212B1 (ko) 2004-10-27 2006-12-01 제일약품주식회사 무정형 레르카니디핀의 제조방법
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
US8097729B2 (en) 2005-09-16 2012-01-17 Glenmark Generics Ltd. Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof
EP2121575A2 (de) * 2007-03-05 2009-11-25 Actavis Group PTC EHF Lercanidipin-hydrochlorid-polymorphe und verbessertes verfahren zur herstellung von 1,1,n-trimethyl-n-(3,3-diphenylpropyl)-2-amino-ethylacetoacetat
WO2008136394A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の製造方法及びその製造中間体
EP2585051B2 (de) 2010-06-23 2020-04-08 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische orale dosierformen mit lercandipin und enalapril und ihren pharmazeutisch akzeptablen salzen
EP2654729B1 (de) 2010-12-24 2016-05-04 KRKA, d.d., Novo mesto Orale homogene pharmazeutische zubereitung enthaltend lercanidipine und enalapril oder ihre pharmazeutische salze zusammen mit einer organischen säure

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) * 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
US5912351A (en) * 1995-05-12 1999-06-15 Recordati, S.A. Chemical And Pharmaceutical Company Anhydrous 1,4-Dihydropyridines and salts thereof

Also Published As

Publication number Publication date
MXPA04001073A (es) 2005-02-17
PE20030350A1 (es) 2003-06-06
JP2005502648A (ja) 2005-01-27
WO2003014085A1 (en) 2003-02-20
IL153916A0 (en) 2003-07-31
DE60203919D1 (de) 2005-06-02
EA200400279A1 (ru) 2004-06-24
KR100912664B1 (ko) 2009-08-17
AU2002331390B2 (en) 2008-06-05
AR037230A1 (es) 2004-11-03
ES2209684T1 (es) 2004-07-01
ITMI20011727A1 (it) 2003-02-06
EP1423367A1 (de) 2004-06-02
HRP20040157A2 (en) 2004-08-31
UY27409A1 (es) 2003-03-31
CN1538958A (zh) 2004-10-20
CN100494175C (zh) 2009-06-03
HUP0401161A2 (hu) 2004-09-28
ITMI20011727A0 (it) 2001-08-06
BR0211738A (pt) 2004-09-28
HUP0401161A3 (en) 2009-04-28
EP1423367B1 (de) 2005-04-27
PL369449A1 (en) 2005-04-18
KR20040030932A (ko) 2004-04-09
IL153916A (en) 2008-07-08
ATE294162T1 (de) 2005-05-15

Similar Documents

Publication Publication Date Title
DK1227088T3 (da) Krystallinsk base af citalopram og hydrochlorid- eller hydrobromidsaltet deraf
NO20031744L (no) Nye ikke-imadazolforbindelser og farmasöytisk preparat omfattende slike
DK1400518T3 (da) Heterocycliske forbindelser og lægemidler
NO20034187L (no) Nye spirotricykliske derivater og anvendelse derav som fosfodiesterase-7 inhibitorer
NO20023319D0 (no) Substituerte glutarimider og deres anvendelse som inhibitorer av IL-12-produksjonen
DE60336567D1 (de) Piezoelektrischer d nnfilmoszillator, piezoelektrisches d nnfilmbauelement und herstellungsverfahren daf r
NO20014135L (no) Nye sulfonamidforbindelser og deres anvendelse
NO20022289L (no) Ny anvendelse og nye N-azabisykloamidderivater
NO20005266D0 (no) Nye substituerte amider, deres fremstilling og anvendelse
NO20040405L (no) Farmasoytiske sammensetninger av amlodipin og atorvastatin.
DK1429769T3 (da) Nye formuleringer og anvendelse deraf
NO20034773D0 (no) Nye ftalazinoner
NO20040390L (no) Krystallinske former VI og VII av atorvastatinkalsium.
NO20021786L (no) Skumdempningsfremgangsmåter og sammensetninger
DK1432683T3 (da) Hidtil ukendte krystallinske polymorfe former af lercanidipinhydrochlorid og fremgangsmåder til fremstilling heraf
NO20033797L (no) Metode og formel for anti-tumor og anti-metastatisk virkning
NO20041187L (no) Metoder og blandinger av nye triazinforbindelser
NO20040479L (no) Solvater av lerkanidipinhydroklorid og nye krystallinske former av lerkanidipinhydroklorid.
NO20035332D0 (no) Nye heterocykliske derivater og medisinsk anvendelse derav
NO20031928L (no) Nye krystall- og solvatformer av ondansetron-hydroklorid og fremgangmsmåterfor fremstilling derav
NO20030822L (no) Nye forbindelser og fremgangsmåter
NO20035331D0 (no) Nye heterocyklisk forbindelse og medisinsk anvendelse derav
DK1429770T3 (da) Nye formuleringer og anvendelse deraf
ATE285408T1 (de) Paroxetin-n-formyl-derivate
NO20042126L (no) Syntese av 2-aralkoksyadenosiner og 2-alkoksyadenosiner

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application